Alvaro J Mejia-Vergara1,2,3, Nicolas Seleme4,5, Alfredo A Sadun4,5, Rustum Karanjia4,5,6,7. 1. Doheny Eye Centers, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. amejiavergara@mednet.ucla.edu. 2. Doheny Eye Institute, Los Angeles, CA, USA. amejiavergara@mednet.ucla.edu. 3. , Pasadena, CA, USA. amejiavergara@mednet.ucla.edu. 4. Doheny Eye Centers, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 5. Doheny Eye Institute, Los Angeles, CA, USA. 6. Department of Ophthalmology, University of Ottawa, Ottawa, Ontario, Canada. 7. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Abstract
PURPOSE: Leber's hereditary optic neuropathy (LHON) is a genetic disease of the mitochondrial genome that mainly affects the retinal ganglion cells (RGC) of the inner retina resulting in central vision loss. New understandings in mitochondrial genetics are helping to elucidate the nuances of conversion and allow for new therapeutic options. RECENT FINDINGS: Appreciation of the mitochondrial fission-fusion balance has allowed for increased understanding of the cascade of events that leads to clinical conversion in LOHN. Mathematical and computational models have helped to interpret the role of ROS in conversion, both as oxidative agents and as signaling molecules for cell death. The conversion from the LHON carrier to the affected patient has been clinically characterized, but the pathophysiology is just beginning to be understood. External stressors alter the mitochondrial dynamics of RGCs, leading to ROS buildup, energy shortages, decreased biogenesis and increased mitophagy, and ultimately axon degeneration and ganglion cell death. New therapeutic alternatives targeting these newly understood pathophysiological changes in the mitochondria and directly addressing the genetic mutations involved in LHON are being developed.
PURPOSE:Leber's hereditary optic neuropathy (LHON) is a genetic disease of the mitochondrial genome that mainly affects the retinal ganglion cells (RGC) of the inner retina resulting in central vision loss. New understandings in mitochondrial genetics are helping to elucidate the nuances of conversion and allow for new therapeutic options. RECENT FINDINGS: Appreciation of the mitochondrial fission-fusion balance has allowed for increased understanding of the cascade of events that leads to clinical conversion in LOHN. Mathematical and computational models have helped to interpret the role of ROS in conversion, both as oxidative agents and as signaling molecules for cell death. The conversion from the LHON carrier to the affected patient has been clinically characterized, but the pathophysiology is just beginning to be understood. External stressors alter the mitochondrial dynamics of RGCs, leading to ROS buildup, energy shortages, decreased biogenesis and increased mitophagy, and ultimately axon degeneration and ganglion cell death. New therapeutic alternatives targeting these newly understood pathophysiological changes in the mitochondria and directly addressing the genetic mutations involved in LHON are being developed.
Authors: D A Mackey; J H Fingert; J Z Luzhansky; P J McCluskey; N Howell; A J H Hall; A B Pierce; J F Hoy Journal: Eye (Lond) Date: 2003-04 Impact factor: 3.775
Authors: Elke K Altpeter; Björn R Blanke; Beate Leo-Kottler; Xuan N Nguyen; Susanne Trauzettel-Klosinski Journal: J Neuroophthalmol Date: 2013-12 Impact factor: 3.042
Authors: Alicia J Kowaltowski; Nadja C de Souza-Pinto; Roger F Castilho; Anibal E Vercesi Journal: Free Radic Biol Med Date: 2009-05-08 Impact factor: 7.376
Authors: Valerio Carelli; Michele Carbonelli; Irenaeus F de Coo; Aki Kawasaki; Thomas Klopstock; Wolf A Lagrèze; Chiara La Morgia; Nancy J Newman; Christophe Orssaud; Jan Willem R Pott; Alfredo A Sadun; Judith van Everdingen; Catherine Vignal-Clermont; Marcela Votruba; Patrick Yu-Wai-Man; Piero Barboni Journal: J Neuroophthalmol Date: 2017-12 Impact factor: 3.042
Authors: Julia Zibold; Bettina von Livonius; Hana Kolarova; Günter Rudolph; Claudia S Priglinger; Thomas Klopstock; Claudia B Catarino Journal: Orphanet J Rare Dis Date: 2022-08-09 Impact factor: 4.303